LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 43

Search options

  1. Article ; Online: Placental growth factor in pre-eclampsia: friend or foe?

    Almaani, Salem J

    Kidney international

    2019  Volume 95, Issue 4, Page(s) 730–732

    MeSH term(s) Animals ; Female ; Humans ; Hypertension ; Mice ; Placenta Growth Factor ; Pre-Eclampsia ; Pregnancy
    Chemical Substances Placenta Growth Factor (144589-93-5)
    Language English
    Publishing date 2019-03-22
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2019.02.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Diabetic Kidney Disease: The "Silent" Majority?

    Yau, Amy / Parikh, Samir V / Almaani, Salem

    Kidney international reports

    2021  Volume 6, Issue 12, Page(s) 2939–2941

    Language English
    Publishing date 2021-11-09
    Publishing country United States
    Document type Editorial
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2021.10.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Letter to the Editor.

    Almaani, Salem / De Rosa, Marcelo / Rovin, Brad H

    Kidney international reports

    2020  Volume 5, Issue 11, Page(s) 2121

    Language English
    Publishing date 2020-08-28
    Publishing country United States
    Document type Journal Article
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2020.08.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Membranous Lupus Nephritis: A Clinical Review.

    Almaani, Salem / Parikh, Samir V

    Advances in chronic kidney disease

    2019  Volume 26, Issue 5, Page(s) 393–403

    Abstract: Membranous lupus nephritis (MLN) (Class V lupus nephritis [LN]) is a distinct form of LN defined by the presence of subepithelial immune complex deposits seen on kidney biopsy. MLN is often associated with the nephrotic syndrome. The histology of MLN ... ...

    Abstract Membranous lupus nephritis (MLN) (Class V lupus nephritis [LN]) is a distinct form of LN defined by the presence of subepithelial immune complex deposits seen on kidney biopsy. MLN is often associated with the nephrotic syndrome. The histology of MLN closely resembles that of idiopathic (primary) membranous nephropathy (pMN). However, MLN typically has abundant mesangial deposits that are absent in primary membranous nephropathy. The clinical presentation, management, and prognosis of MLN differ from that of the proliferative forms of LN (Class III, IV, or Mixed III/IV + V). Although immunosuppressive therapy is often warranted in MLN, the optimal treatment regimen remains unclear. Here we describe the clinical presentation, histologic features, and natural history of MLN. We also review the role of supportive treatment and discuss when to deploy immunosuppressive management in MLN.
    MeSH term(s) Glomerular Basement Membrane/pathology ; Humans ; Immunosuppressive Agents/pharmacology ; Lupus Nephritis/pathology ; Lupus Nephritis/physiopathology ; Lupus Nephritis/therapy ; Nephrotic Syndrome/diagnosis ; Nephrotic Syndrome/etiology ; Prognosis
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2019-11-15
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ISSN 1548-5609 ; 1548-5595
    ISSN (online) 1548-5609
    ISSN 1548-5595
    DOI 10.1053/j.ackd.2019.08.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: B-cell therapy in lupus nephritis: an overview.

    Almaani, Salem / Rovin, Brad H

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

    2018  Volume 34, Issue 1, Page(s) 22–29

    Abstract: Systemic lupus erythematosus (SLE) is an autoimmune multisystem disease that commonly affects the kidneys. It is characterized by persistent autoantibody production that targets a multitude of self-antigens. B-cells, plasmablasts and plasma cells, as the ...

    Abstract Systemic lupus erythematosus (SLE) is an autoimmune multisystem disease that commonly affects the kidneys. It is characterized by persistent autoantibody production that targets a multitude of self-antigens. B-cells, plasmablasts and plasma cells, as the source of these autoantibodies, play a major role in the development of lupus nephritis (LN), and are therefore promising therapeutic targets. To date, however, randomized clinical trials of B-cell therapies in LN have not lived up to expectations, whereas uncontrolled cohort and observational studies of B-cell antagonists have been more promising. In this article, we will review the current experience with B-cell therapy in LN and highlight the pitfalls that may have limited their success. We will conclude by suggesting B-cell-centric approaches to the management of LN based on what has been learned from the overall B-cell experience in SLE.
    MeSH term(s) Animals ; B-Lymphocytes/drug effects ; B-Lymphocytes/immunology ; Cell- and Tissue-Based Therapy/methods ; Humans ; Lupus Nephritis/immunology ; Lupus Nephritis/therapy
    Language English
    Publishing date 2018-08-27
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 90594-x
    ISSN 1460-2385 ; 0931-0509
    ISSN (online) 1460-2385
    ISSN 0931-0509
    DOI 10.1093/ndt/gfy267
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Reimagining the kidney biopsy in the era of diagnostic biomarkers of glomerular disease.

    Rovin, Brad H / Almaani, Salem / Malvar, Ana

    Kidney international

    2019  Volume 95, Issue 2, Page(s) 265–267

    Abstract: Anti-phospholipase A2 receptor (PLA2R) antibody is a specific biomarker for primary membranous nephropathy (MN). Testing positive for anti-PLA2R has been postulated to establish a diagnosis of MN in the absence of a kidney biopsy. Bobart et al. tested ... ...

    Abstract Anti-phospholipase A2 receptor (PLA2R) antibody is a specific biomarker for primary membranous nephropathy (MN). Testing positive for anti-PLA2R has been postulated to establish a diagnosis of MN in the absence of a kidney biopsy. Bobart et al. tested this hypothesis and concluded that anti-PLA2R positivity is sufficient to diagnose primary MN and initiate treatment in a subset of patients with nephropathy. This biomarker, however, does not render the kidney biopsy obsolete, but encourages the application of molecular analyses to renal pathology to keep the biopsy relevant.
    MeSH term(s) Antibodies ; Biomarkers ; Biopsy ; Glomerulonephritis, Membranous ; Humans ; Receptors, Phospholipase A2
    Chemical Substances Antibodies ; Biomarkers ; Receptors, Phospholipase A2
    Language English
    Publishing date 2019-01-21
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2018.11.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Update on Lupus Nephritis: Core Curriculum 2020.

    Parikh, Samir V / Almaani, Salem / Brodsky, Sergey / Rovin, Brad H

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2020  Volume 76, Issue 2, Page(s) 265–281

    Abstract: Systemic lupus erythematosus is a multisystem autoimmune disease that commonly affects the kidneys. Lupus nephritis (LN) is the most common cause of kidney injury in systemic lupus erythematosus and a major risk factor for morbidity and mortality. The ... ...

    Abstract Systemic lupus erythematosus is a multisystem autoimmune disease that commonly affects the kidneys. Lupus nephritis (LN) is the most common cause of kidney injury in systemic lupus erythematosus and a major risk factor for morbidity and mortality. The pathophysiology of LN is heterogeneous. Genetic and environmental factors likely contribute to this heterogeneity. Despite improved understanding of the pathogenesis of LN, treatment advances have been few and risk for kidney failure remains unacceptably high. This installment in the Core Curriculum of Nephrology provides an up-to-date review of the current understanding of LN epidemiology, pathogenesis, diagnosis, and treatment. Challenging issues such as the management of LN in pregnancy, timing of transplantation, and the evolving role of corticosteroid use in the management of LN are discussed. We review the currently accepted approach to care for patients with LN and highlight deficiencies that need to be addressed to better preserve long-term kidney health and improve outcomes in LN.
    MeSH term(s) Adaptive Immunity/immunology ; Adrenal Cortex Hormones/therapeutic use ; Age Distribution ; Autoantibodies/immunology ; Autoimmunity/immunology ; Biopsy ; Cyclophosphamide/therapeutic use ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Immunity, Innate/immunology ; Immunologic Factors/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Induction Chemotherapy ; Kidney Failure, Chronic/etiology ; Kidney Failure, Chronic/therapy ; Kidney Transplantation ; Lupus Nephritis/drug therapy ; Lupus Nephritis/epidemiology ; Lupus Nephritis/pathology ; Lupus Nephritis/physiopathology ; Maintenance Chemotherapy ; Male ; Mycophenolic Acid/therapeutic use ; Pregnancy ; Pregnancy Complications ; Renal Dialysis ; Urinalysis
    Chemical Substances Adrenal Cortex Hormones ; Autoantibodies ; Immunologic Factors ; Immunosuppressive Agents ; Hydroxychloroquine (4QWG6N8QKH) ; Cyclophosphamide (8N3DW7272P) ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2020-03-24
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2019.10.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: ANCA-Associated Vasculitis: An Update.

    Almaani, Salem / Fussner, Lynn A / Brodsky, Sergey / Meara, Alexa S / Jayne, David

    Journal of clinical medicine

    2021  Volume 10, Issue 7

    Abstract: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target ... ...

    Abstract Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target neutrophil antigens. The two major antigens targeted by ANCAs are leukocyte proteinase 3 (PR3) and myeloperoxidase (MPO). AAV can be classified into 3 categories based on patterns of clinical involvement: namely, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA). Clinically, AAV involves many organ systems including the lungs, kidneys, skin, and nervous system. The prognosis of AAV has improved dramatically due to advances in the understanding of its pathogenesis and treatment modalities. This review will highlight some of the recent updates in our understanding of the pathogenesis, clinical manifestations, and treatment options in patients with AAV focusing on kidney involvement.
    Language English
    Publishing date 2021-04-01
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm10071446
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits.

    Almaani, Salem / Parikh, Samir V / Satoskar, Anjali A / Bumma, Naresh / Rovin, Brad H / Sharma, Nidhi / Efebera, Yvonne / Ayoub, Isabelle

    Kidney international reports

    2021  Volume 6, Issue 8, Page(s) 2203–2206

    Language English
    Publishing date 2021-05-20
    Publishing country United States
    Document type Journal Article
    ISSN 2468-0249
    ISSN (online) 2468-0249
    DOI 10.1016/j.ekir.2021.05.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Impact of concurrent glomerulonephritis on outcomes of diffuse alveolar haemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis.

    Cohen, Sarah P / Wodarcyk, Andrew J / Wong, Alexander / Patterson, Kevin C / Lyons, Matthew I / Barnes, Alexis / Strickland, Alan / Pan, Xueliang / Almaani, Salem / Meara, Alexa S / Crouser, Elliott D / Wewers, Mark D / Fussner, Lynn A

    Clinical and experimental rheumatology

    2023  

    Abstract: Objectives: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) commonly presents with diffuse alveolar haemorrhage (DAH) and/or glomerulonephritis. Patients who present with DAH but without kidney involvement have been understudied.!# ...

    Abstract Objectives: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) commonly presents with diffuse alveolar haemorrhage (DAH) and/or glomerulonephritis. Patients who present with DAH but without kidney involvement have been understudied.
    Methods: Patients with DAH diagnosed by bronchoscopy and attributed to AAV over 8.5 years were retrospectively identified through electronic medical records and bronchoscopy reporting software. Patients with end-stage kidney disease (ESKD) or prior kidney transplant were excluded. Characteristics, treatments, and outcomes were abstracted.
    Results: 30 patients were identified with DAH secondary to AAV. Five with ESKD or prior kidney transplant, and one with concomitant anti-glomerular basement membrane disease, were excluded, leaving 24 patients for analysis. At the time of qualifying bronchoscopy, six patients had no apparent kidney involvement by AAV, while eight of 18 with kidney involvement required dialysis. Of the eight patients dialysed during the initial hospitalisation, four were declared to have ESKD and three died in the subsequent year (one of whom did both). None of the 16 patients without initial dialysis requirement developed kidney involvement requiring dialysis in the subsequent year, though three of the six without initial evidence of kidney involvement by AAV ultimately developed it. No patient without initial kidney involvement died during follow-up.
    Conclusions: In our cohort, patients with DAH due to AAV without initial kidney involvement did not develop kidney involvement requiring dialysis or die during the follow-up period, though half of patients without initial evidence of kidney involvement subsequently developed it. Larger studies are warranted to better characterise this population and guide medical management.
    Language English
    Publishing date 2023-11-17
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 605886-3
    ISSN 1593-098X ; 0392-856X
    ISSN (online) 1593-098X
    ISSN 0392-856X
    DOI 10.55563/clinexprheumatol/s9su9e
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top